Interindividual variability of atorvastatin treatment influence on the MPO gene expression in patients after acute myocardial infarction

• Authors: Grażyna Sygitowicz , Agata Maciejak , Joanna Piniewska-Juraszek , Maciej Pawlak , Monika Góra , Beata Burzyńska , Mirosław Dłużniewski , Grzegorz Opolski , Dariusz Sitkiewicz
• Languages of publication: EN

Abstracts

EN

Myeloperoxidase (MPO) and C-reactive protein (CRP) may play critical roles in generation of oxidative stress and the development of the systemic inflammatory response. The aim of the study was to determine the effect of atorvastatin therapy on the MPO gene expression and its plasma level in relation to lipids level lowering and an anti-inflammatory response in patients after acute myocardial infarction. The research material was represented by 112 samples. Thirty-eight patients with first AMI receiving atorvastatin therapy (40 mg/day) and followed up for one month were involved in the study. The relative MPO gene expression in peripheral blood mononuclear cells (PBMCs) was examined using RT-qPCR in 38 patients before-, 38 patients after-therapy and in 36 patients as the control group. The plasma concentrations of MPO and serum concentrations of biochemical parameters were determined using commercially available diagnostic tests. After one month of atorvastatin therapy, in 60.5% patients a decrease of MPO gene expression, whereas in 39.5% patients an increase, was observed. The plasma MPO levels behaved in the same way as the MPO gene expression. However, the serum lipids and CRP concentrations were significantly lower after one month of atorvastatin therapy in both groups of patients - with decreased and increased MPO gene expression. Atorvastatin exhibited a different effect on MPO gene expression and its plasma level. Short-term atorvastatin therapy resulted in lipid lowering and anti-inflammatory activity in patients after AMI, independently of its effect on MPO gene expression. The molecular mechanisms of this phenomenon are not yet defined and require further research.

Keywords

EN

MPO gene expression; myeloperoxidase; C-reactive protein; atorvastatin; acute myocardial infarction

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2016
• Volume: 63
• Issue: 1
• Pages: 89-95

Dates

published

2016

received

2015-03-30

revised

2015-10-30

accepted

2015-11-22

(unknown)

2015-12-23

Contributors

author

Grażyna Sygitowicz

• Department of Medical Laboratory Diagnostics, Medical University of Warsaw, Warsaw, Poland

author

Agata Maciejak

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

author

Joanna Piniewska-Juraszek

• Department of Cardiology, Hypertension & Internal Medicine, Medical University of Warsaw, Warsaw, Poland

author

Maciej Pawlak

• 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

author

Monika Góra

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

author

Beata Burzyńska

• Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Warsaw, Poland

author

Mirosław Dłużniewski

• Department of Cardiology, Hypertension & Internal Medicine, Medical University of Warsaw, Warsaw, Poland

author

Grzegorz Opolski

• 1st Department of Cardiology, Medical University of Warsaw, Warsaw, Poland

author

Dariusz Sitkiewicz

• Department of Medical Laboratory Diagnostics, Medical University of Warsaw, Warsaw, Poland

References

• Aminian A, Boudjeltia KZ, Babar S, Van Antwerpen P, Lefebvre P, Crasset V, Leone A, Docobu J, Friart A, Vanhaeverbeek M (2009) Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction. Eur J Intern Med 20: 527-532.
• Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari T, Siasos G, Papageorgion N, Papadimitriou CA, Dimopoulos MA, Stefanadis C (2010) Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: A randomized placebo-controlled study. Atherosclerosis 210: 194-198.
• Apple FS, Smith SW, Pearce LA, Schulz KM, Ler R, Murakami MM (2011) Myeloperoxidase improves risk stratification in patients with ischemia and normal cardiac troponin I concentrations. Clin Chem 57: 603-608.
• Boudjeltia KZ, Moguilevsky N, Legssyer I, Babar S, Guillaume M, Delree P, Vanhaeverbeek M, Brohee D, Ducobu J, Remade C (2004) Oxidation of low density lipoproteins by myeloperoxidase at the surface of endothelial cells: an additional mechanism to subendothelium oxidation. Biochem Biophys Res Commun 325: 434-438.
• Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL, Vandesompele J, Wittwer CT (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
• Byun J, Mueller DM, Fabjan JS, Heinecke JW (1999) Nitrogen dioxide radical generated by the myeloperoxidase-hydrogen peroxide-nitrite system promotes lipid peroxidation of low density lipoprotein. FEBS Letters 455: 243-246.
• Castellani LW, Chang JJ, Wang X, Lusis AJ, Reynolds WF (2006) Transgenic mice express human MPO -463C/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463C males. J Lipid Res 47: 1366-1377.
• Chevrier I, Tregouet DA, Massonnet-Castel S, Beaune P, Loriot MA (2006) Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: Genetic determinants for atherosclerosis? Atherosclerosis 188: 150-154.
• Davignon J (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109: III39-III43.
• Eggers KM, Dellborg M, Johnston N, Oldgren J, Swahn E, Venge P, Lindahl B (2010) Myeloperoxidase is not useful for the early assessment of patients witch chest pain. Clin Biochem 43: 240-245.
• Goldmann BU, Rudolph V, Rudolph TK, Holle AK, Hillebrandt M, Meinertz T, Baldus S (2009) Neutrophil activation precedes myocardial injury in patients with acute myocardial infarction. Free Rad Biol Med 47: 79-83.
• Greenwood J, Mason JC (2007) Statins and the vascular endothelial inflammatory response. Trends Immunol 28: 88-98.
• Kumar AP, Reynolds WF (2005) Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 331: 442-451.
• Lau D, Baldus S (2006) Myeloperoxidase and its contributory role in inflammatory vascular disease. Pharmacol Ther 111: 16-26.
• Leszczynska A, Gora M, Plochocka D, Hoser G, Szkopinska A, Koblowska M, Iwanicka-Nowicka R, Kotlinski M, Rawa K, Kiliszek M, Burzynska B (2011) Different statins produce highly divergent changes in gene expression profiles of human hepatoma cells: a pilot study. Acta Biochim Pol 58: 635-639.
• Ndrepepa G, Braun S, Schomig A, Kastrati A (2011) Impact of therapy with statins, beta-blockers and angiotensin-converting enzyme inhibitors on plasma myeloperoxidase in patients with coronary artery disease. Clin Res Cardiol 100: 327-333.
• Nicholls SJ, Hazen SL (2005) Myeloperoxidase and Cardiovascular Disease. Arterioscler Thromb Vasc Biol 25: 1102-1111.
• Nikpoor B, Turecki G, Fournier C, Theroux P, Rouleau GA (2001) A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J 142: 336-339.
• Olsson AG (2001) Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. Am J Cardiol 87: 33B-36B.
• Pedersen TR (2004) Randomised trial of cholesterol lowering in 4444patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atherosclerosis Suppl. 5: 81-87.
• Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
• Reynolds WF, Kumar AP, Piedrafita FJ (2006) The human myeloperoxidase gene is regulated by LXR and PPARα ligands. Biochem Biophys Res Commun 349: 846-854.
• Scharnagi H, Kleber ME, Genser B, Kickmaier S, Renner W, Weihrauch G, Grammer T, Rossmann C, Winkelmann BR, Boehm BO, Sattler W, Marz W, Malle E (2014) Association of myeloperoxidase with total and cardiovascular mortality in individuals undergoing coronary angiography-The LURIC study. Int J Cardiol 174: 96-105.
• The Writing Group on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction (2012) Third universal definition of myocardial infarction. Eur Heart J 33: 2551-2567.
• Tsimikas S, Willerson JT, Ridker PM (2006) C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47: C19-C31.
• Vasilyev N, Williams T, Brennan ML, Unzek S, Zhou X, Heinecke JW, Spitz DR, Topol EJ, Hazen SL, Penn MS (2005) Myeloperoxidase-generated oxidants modulate left ventricular remodeling but not infarct size after myocardial infarction. Circulation 112: 2812-2820.
• Wainstein RV, Wainstein MV, Ribeiro JP, Dornelles LV, Tozzati P, Ashton-Prolla P, Ewald IP, Vietta G, Polanczyk CA (2010) Association between myeloperoxidase polymorphism and its plasma levels with severity of coronary artery disease. Clin Biochem 43: 57-62. http://dx.doi.org.10.1016/j.clinbiochem.2009.07.022.
• Wang CY, Liu PY, Liao JK (2008) Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 14: 37-44.
• Yang JP, Wang WB, Yang XX, Yang L, Ren L, Zhou FX, Hu L, He W, Li BY, Zhu Y, Jiang HG, Zhou YF (2013) The MPO-463C a polymorphism and lung cancer: a meta-analysis based on 22 case-control studies. PLoS One 8: e65778.
• Zhang R, Brennan ML, Fu X, Aviles RJ, Pearce GL, Penn MS, Topol EJ, Sprecher DL, Hazen SL (2001) Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 286: 2136-2142.
• Zhou T, Zhou SH, Qi SS, Shen XQ, Zeng GF, Zhou HN (2006) The effect of atorvastatin on serum myeloperoxidase and CRP levels in patients with acute coronary syndrome. Clin Chim Acta 368: 168-172.

Identifiers

DOI

10.18388/abp.2015_1014